Welcome to our dedicated page for BOUNDLESS BIO SEC filings (Ticker: BOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles SEC filings for Boundless Bio, Inc. (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology and ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers. The filings provide official details on the company’s financial condition, governance, and key corporate events.
Among the documents available are Current Reports on Form 8-K. For example, Boundless Bio filed 8-Ks dated August 5, 2025, and November 5, 2025, each noting that the company issued press releases announcing financial results for the quarters ended June 30, 2025, and September 30, 2025, respectively. These 8-Ks explain that the earnings press releases are furnished as exhibits and describe how they are treated under Section 18 of the Securities Exchange Act of 1934.
An additional Form 8-K dated June 23, 2025, reports the results of the company’s annual meeting of stockholders. This filing summarizes stockholder votes on the election of Class I directors to serve until the 2028 annual meeting of stockholders and on the ratification of KPMG LLP as Boundless Bio’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Vote totals for each proposal are presented in tabular form within the filing.
In its press releases, Boundless Bio also directs readers to annual and quarterly reports, such as its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarter ended September 30, 2025, for detailed risk factor discussions and additional financial and operational information. Those filings, together with 8-Ks, form the core of the company’s SEC disclosure record.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items such as earnings announcements, stockholder vote outcomes, and updates referenced in 8-Ks. Real-time integration with the SEC’s EDGAR system means new BOLD filings appear promptly, while structured views make it easier to locate specific forms, including 8-Ks related to financial results and governance matters. This allows users to review Boundless Bio’s regulatory history and disclosures that frame the development of its ecDTx pipeline and clinical programs.
Director Jonathan E. Lim of Boundless Bio received a stock option grant on June 23, 2025, representing a significant insider transaction. The key details include:
- Granted 24,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The grant was executed under direct ownership, with Jessica Oien signing as attorney-in-fact. This equity compensation aligns with standard director compensation practices and demonstrates the company's commitment to retaining board talent through long-term incentives.
Form 4 Overview: On 06/23/2025, Boundless Bio, Inc. (ticker BOLD) filed a Form 4 disclosing a grant of derivative securities to director and 10% owner Kristina Burow.
- Security granted: Stock option (right to buy)
- Quantity: 16,000 options
- Exercise price: $1.03 per share
- Vesting schedule: Monthly over 12 months beginning 06/23/2025; any unvested portion accelerates to the next annual shareholder meeting if earlier.
- Expiration: 06/22/2035
- Ownership form after transaction: Direct (16,000 derivative securities)
No non-derivative share transactions were reported. The filing represents routine director compensation rather than an open-market purchase, and it does not include financial performance metrics or earnings data.
Boundless Bio director Nancy Whiting received a stock option grant on June 23, 2025, according to a Form 4 filing. The key details of the transaction include:
- Granted 16,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The options were granted as part of director compensation and are subject to continued service on the company's board. The transaction was executed under direct ownership, with Jessica Oien signing as attorney-in-fact for Nancy Whiting.
Boundless Bio, Inc. (Nasdaq: BOLD) filed a Form 8-K detailing the results of its 23 June 2025 annual meeting of stockholders.
- Director elections: Class I nominees Christine Brennan, Ph.D. (9,252,440 for / 5,046,258 withheld) and Nancy Whiting, Pharm.D. (9,758,214 for / 4,540,484 withheld) were elected to serve until the 2028 annual meeting; 3,540,518 broker non-votes were recorded for each candidate.
- Auditor ratification: Shareholders ratified KPMG LLP as independent registered public accounting firm for fiscal 2025 with 17,791,309 votes for, 47,807 against and 100 abstentions.
No other matters were brought before shareholders and no additional material disclosures were made.